Follow the money: How the billions of dollars that flow from smokers in poor nations to companies in rich nations greatly exceed funding for global tobacco control and what might be done about it by Callard, Cynthia
Follow the money: How the billions of dollars that
ﬂow from smokers in poor nations to companies in
rich nations greatly exceed funding for global tobacco
control and what might be done about it
Cynthia Callard
ABSTRACT
The business of selling cigarettes is increasingly
concentrated in the hands of ﬁve tobacco companies
that collectively control almost 90% of the world’s
cigarette market, four of which are publicly traded
corporations. The economic activities of these cigarette
manufacturers can be monitored through their reports to
shareholders and other public documents. Reports for
2008 show that the revenues of these ﬁve companies
exceeded $300 billion, of which more than $160 billion
was provided to governments as taxes, and that
corporate earnings of the four publicly traded companies
were over $25 billion, of which $14 billion was retained
after corporate income taxes were paid. By contrast,
funding for domestic and international tobacco control is
not reliably reported. Estimated funding for global
tobacco control in 2008, at $240 million, is signiﬁcantly
lower than resources provided to address other high-
mortality global health challenges. Tobacco control has
not yet beneﬁted from the innovative ﬁnance
mechanisms that are in place for HIV/AIDS, tuberculosis
and malaria. The Framework Convention On Tobacco
Control (FCTC) process could be used to redirect some of
the earnings from transnational tobacco sales to fund
FCTC implementation or other global health efforts.
INTRODUCTION
Tobacco use is a global health problem, and the
business activities which fuel tobacco use have
garnered strength from the economic, cultural and
trade dimensions of globalisation.
1
Indicative of the increased globalisation of the
tobacco market is the extent to which domestic
tobacco producers have been replaced by multina-
tional corporations. While it may be difﬁcult to
visualise the number of smokers worldwide (1.3
billion) or the number of cigarettes smoked in
recent years (5.6 trillion in 2008),
2 the number of
tobacco companies that make most of these ciga-
rettes can be can be counted on the ﬁngers of one
hand. They are British American Tobacco, the
China National Tobacco Company, Imperial
Tobacco, Japan Tobacco and Philip Morris Interna-
tional. Among the companies that have in recent
years been acquired by or merged with these
companies are Gallaher, Lakson, Reemstma, Roth-
mans, Sampoerna, SEITA, Tabacalera and Tekel.
3 In
only a few nations (such as China, the USA, Japan,
Thailand, Egypt) is the tobacco market operated by
companies headquartered in that country,
3 and the
global market share of multinational tobacco
companies has grown signiﬁcantly over the past
two decades (table 1).
The world’s largest tobacco company is owned
and controlled by the Chinese government and
operates almost exclusively in China; in 2008 it
accounted for 38% of the world’s cigarette sales.
5
While estimates differ of the market share of the
largest companies operating outside China,
8e10
Euromonitor
2 reports a further 50% of the world
market is supplied by: British American Tobacco
and its associates, (16.4% global market share when
sales by associated companies like Reynolds Amer-
ican are included); Philip Morris International
(15.5%); Japan Tobacco (10.9%); and Imperial
Tobacco (5.9%). The remaining market is served by
companies which operate predominantly in
domestic or regional markets, such as US-based
Altria/Philip Morris USA (3%) and Lorillard (<1%);
Egypt’s Eastern Tobacco (1.2%); Korea’s KT&G
(1.8%); the Thai Tobacco Monopoly; the Taiwan
Tobacco & Liquor Corporation; the Vietnam
National Tobacco Corporation; and Bulgaria’s
Bulgartabac (all under 1%).
21 1 e13
One consequence of global concentration is the
relative ease of measuring the tobacco economy by
using information provided to shareholders and
ﬁnancialanalystsincompliancewithstockexchange
and other regulations. Comparative data on tobacco
control are less robust or routine but, nonetheless,
allows comparison between the ﬁnancial beneﬁts to
tobacco company owners that result from tobacco
use and the ﬁnancial resources provided by govern-
ments and others to reduce tobacco use.
METHODS
Sales data, revenue and income of the largest
publicly traded tobacco companies for the
2008 ﬁscal year were collected from corporate
annual reports of the companies reviewed,
14e17
investor presentations
8e10 18 and from other trade
sources.
231 92 0Information on expenditures on
tobacco control and selected health issues during
this same general time period were gathered from
publicly available sources.
15 16 These data were
compiled to provide a snapshot of the global
economies of tobacco sales and tobacco control in
2007 and 2008.
Some adjustments to the data were required to
allow for comparability. The companies reviewed
deﬁned key ﬁnancial terms differently, reported on
different time periods, presented data in different
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Research papercurrencies and used different regional groupings for their
markets. To allow for better comparison of data:
< The terms (a) revenues, (b) earnings and (c) proﬁts were used
to mean (a) gross value of tobacco sales including excise taxes,
(b) value of tobacco sales after costs of production and excise
taxes have been subtracted and (c) net corporate proceeds
after income taxes, extraordinary items and other expenses
have been subtracted.
< The business activities reviewed were those in the ﬁscal year
with the most months in 2008: that is the ﬁscal years ending
30 September 2008 (Imperial Tobacco), 31 December 2008
(British American Tobacco, Altria and Philip Morris Interna-
tional) and 31 March 2009 (Japan Tobacco).
< No adjustment was made to regional or geographical
categories or terms, which are presented as provided by the
companies. Information on the groupings used by the
companies, although often vague can be found in their
annual reports.
14e17
< For companies that did not report results in US dollars, local
currencies were converted to US dollars at the average annual
rate in 2008, as stated in table 2.
< This study is limited to the sale of manufactured cigarettes
and ﬁne-cut tobacco intended for use in cigarette form (ie,
RYO/roll-your-own). These two product categories were
combined by calculating 0.7 g of ﬁne-cut tobacco as
equivalent to a manufactured cigarette. Oral tobacco, shisha
tobacco, pipe tobacco, bidis, etc, were not included in this
study.
RESULTS
In 2008, British American Tobacco, Philip Morris International,
Japan Tobacco International and the Imperial Tobacco Group
shared about $220 billion in revenues from tobacco sales. After
these companies paid their production costs and remitted tobacco
taxes to governments, their earnings were $25 billion, approxi-
mately $0.18 for each package of 20 cigarettes they sold. After
paying corporate income taxes and other such expenses, they
retained almost $14 billion in proﬁts (about $0.10 per package).
Almost nine-tenths of the sales on which these earnings were
based were in foreign marketsdthat is, from sales in countries
other than the country in which the company is ofﬁcially and
operationally headquartered. On average, each carton of 200
cigarettes sold by Philip Morris International resulted in a return
of $2.30, while Imperial Tobacco’s earnings on foreign sales were
$1.78 per carton, BAT’s were $1.60 and Japan Tobacco’sw e r e
$1.10 per carton. These results are presented in table 2.
14e17
Results by company
China’s National Tobacco Company (CNTC)
5
Chinese smokers consume 38% of the world’s cigarettes, and
the 2143 billion cigarettes they smoked in 2008 were all sold
through the State Tobacco Monopoly Administration (STMA),
and were almost all manufactured by the China National
Tobacco Corporation (CNTC) which functions as an umbrella
agency for China’s many domestic companies. Like its multi-
national counterparts, the Chinese tobacco industry is under-
going signiﬁcant restructuring. The CNTC sold relatively few
(13 billion) cigarettes outside China in 2008, although it has
announced intentions to expand its foreign trade, and has
entered an agreement with Philip Morris International to
distribute its ‘heritage’ brands in international markets.
23 24
Many distinctions between the operations and reporting of
CNTC and the publicly traded multinationals make it inap-
propriate to compare business results with other companies.
Euromonitor reports that in 2008 the total tax revenue of the
Chinese industry was $64 billion (CNY (Chinese yuan
renminbi) 450 billion) and that the value of sales was $105
million (CNY 732).
British American Tobacco (BAT)
15
BAT is based in the UK but, for historical business and legal
reasons, has a much smaller presence in the UK and operates
indirectly (through, Reynolds American) in the USA. In 2008, it
directly managed the manufacture and sale of 716 billion ciga-
rettes and through the associated companies in which it is the
largest shareholder, it indirectly managed the sale of an addi-
tional 204 billion cigarettes. BATclaims to sell three-quarters of
its production in developing countries. Transnational earnings
from BAT’s global operations exceeded $7 billion in 2008.
Philip Morris International (PMI)
19
Philip Morris brands have been sold internationally for decades,
but Philip Morris International (PMI) was created as recently as
2008, when it was spun off from Altria. Although PMI has its
operating headquarters in Switzerland, its legal headquarters is
in the USA. PMI and Altria continue to operate in tandem: the
brands that are sold by Altria in the USA are sold in other parts
of the world by PMI,
13 including the world’s best-selling ciga-
rette, Marlboro, which has 13% market share of the cigarettes
sold outside China.
18 In 2008, Philip Morris International sold
870 billion cigarettes and its earnings exceeded $10 billion. Fewer
than half its sales were in OECD member countries.
Table 1 Global cigarette market share, major companies, 1991 and
2008
1991
4 2008
25 e7
Billion
cigarettes
Share of
global market
(%)
Billion
cigarettes
Share of
global market
(%)
China National Tobacco
Company (CNTC)
1687 32.0 2143 38.3
Philip Morris International 640 12.2 869 15.5
Altria/Philip Morris USA 169 3.0
BAT (and Canada’s Imperial
and India’s ITC)
529 10.1 830 14.8
Japan Tobacco 275 5.2 612 10.9
RJ Reynolds/Reynolds
Americany
135 2.6 90 1.6
Rothmans International 120 2.3 *
Korea Tobacco and Ginseng
(South Korea)
90 1.7 102 1.8
Bulgartabac (Bulgaria) 80 1.5 13 0.2
American Brands 78 1.5 *
Tekel (Turkey) 58 1.1 *
Tabacalera (Spain) 57 1.1 *
Eastern Tobacco (Egypt) 54 1.0 68 1.2
Reemtsma (Germany) 53 1.0 *
Seita (France) 50 0.9 *
AAMS (Italy) 47 0.9 *
Thailand Tobacco Monopoly 38 0.7 22 0.4
Lorillard 37 0.7 37 0.7
Imperial (UK) 32 0.6 329 5.9
Austria Tabak (SM) 21 0.4 *
Others 1189 23 259 4.6
Total 5267 100 5600 100
*No longer in operation.
yNow 40% owned by BAT and reported with BAT in this study.
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Research paperThe Imperial Group (ITG)
16
For many years, the Imperial Tobacco Group PLC (ITG) sold few
cigarettes outside the UK, but in recent years it has globalised its
business through the acquisition of other companies, such as
Reemtsma, Altadis and Commonwealth Brands. In 2008 only 25
billion of its total sales of 329 billion cigarettes were in the UK.
ITG’s sales are concentrated in the Americas and Europe, with
only one-ﬁfth of its market outside these continents, but almost
half of its sales are in developing countries and newly industri-
alised states (particularly eastern Europe). Earnings from Impe-
rial Tobacco’s global operations approached $3 billion in 2008,
with a further $1 billion in earnings from the UK.
Table 2 Sales, revenues, earnings and proﬁts of the CNTC and major tobacco multinational tobacco companies, 2008y
Cigarettes sold
(billions)
Revenues from
tobacco
sales (millions)
Earnings from
tobacco sales
(millions)
Corporate proﬁts
after tax (millions)
Earnings
per pack
CNY US$ US$
China National Tobacco Company 2143 732300 105347 * * * * *
GPB US$ GPB US$ GPB US$
British American Tobacco 920 33921 62262 4075 7480 2659 4881 0.16
Direct operations 716 3717 6822 0.19
Americas 161 1052 1931 0.24
Western Europe 123 760 1395 0.23
Asia Paciﬁc 180 924 1696 0.19
Eastern Europe 137 468 859 0.13
Africa and Middle East 114 513 942 0.17
Associates 204 503 923 0.09
Reynolds American 90 339 622 0.14
ITC 81 117 215 0.05
Other 33 47 86 0.05
Developing countries 544 (76%)
Developed countries 172 (24%)
US$ US$ US$ US$
Philip Morris International 869 63640 10248 6890 0.23
European Union 243 4738 0.39
Eastern Europe, Middle East and Africa 303 3119 0.21
Asia 224 2057 0.18
Latin America and Canada 99 520 0.11
Non-OECD countries 469 (54%) 3279 0.27
OECD countries 399 (46%) 6657 0.55
GPB US$ GPB US$ GPB US$ US$
Imperial Tobacco Group 329 15650 28725 2107 3867 441 809 0.24
United Kingdom 25 584 1040 0.86
Germany 30 309 550 0.38
Spain 25 150 267 0.22
Rest of European Union 77 494 879 0.24
Americas 16 166 296 0.38
Rest of world 156 404 719 0.10
Developing countries 175 (53%)
Developed countries 154 (47%)
JPY US$ JPY US$ JPY US$ US$
Japan Tobacco 612 6832307 66049 353031 3413 123400 1193 0.11
International Tobacco 452 3118319 30145 174772 1690 0.07
North and Central Europe 51
CIS countries 220
South and West Europe 64
Rest of world 118
Domestic tobacco 160 3200494 30940 188259 1820 0.23
Major manufacturers
Domestic salesdChina 2143 * *
Domestic salesdother 185 2892 0.31
International sales 2545 22213 0.17
Other manufacturers 727
Total 5600 326023 25104 13773 0.18
*Comparable ﬁgures not available.
yCurrency converted at the yearly average rates (US$ ¼ 1; CNY ¼ 6.95; GBP ¼ 0.55; JNY ¼ 103.4).
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14 25
Almost three-quarters of the 613 billion cigarette manufactured
and sold by Japan Tobacco in 2008 were sold through its wholly
owned subsidiary, Japan Tobacco International. Although JT is
a publicly traded company, the Japanese government holds
a 50% ownership and the legal authority to supervise its oper-
ations. Japan Tobacco also maintains non-tobacco operations,
including pharmaceutical products and food, but less than 5% of
its earnings come from these other sources. Transnational
earnings from Japan Tobacco’s international operations were
$1.7 billion in 2008, and its domestic tobacco earnings were $1.8
billion.
Government revenues from tobacco
From the sale of cigarettes made by the four largest tobacco
multinationals, governments received over $100 billion in
tobacco speciﬁc taxes and almost $7 billion in corporate income
taxes.
14e17 Total payments to government exceed $170 billion
whenpaymentsbyothertobaccocompaniesareincluded.
12 13 19 26
These tax payments, as reported in the annual reports are
displayed in table 3, although company reports do not state to
which government these taxes were remitted.
In addition to tax revenues, governments which have
complete or partial ownership in tobacco companies receive
income in the form of remittances or dividend payments. This
will occur when the government owns and controls a state
monopoly, such as Egypt’s Eastern Company, Vietnam’s
VINATABA, Thailand’s Tobacco Monopoly and Taiwan’s
Tobacco & Liquor Corporation. Governments which do not own
state monopolies may own shares in publicly traded tobacco
companies, and will receive dividend payments or other forms of
proﬁt sharing from these investments. On the basis of the
holdings by the government of Japan in Japan Tobacco, it likely
received $275 million in dividend payments for 2008, about half
of which was attributable to proﬁts on international tobacco
sales.
14 Governments may invest in tobacco companies head-
quartered in other countries; public pension investments by
governments of Canada and the Canadian province of Quebec
are estimated to have resulted in combined dividend payments
totalling $20 million from the proﬁts of international tobacco
sales in 2008.
27
Government investments in domestic and global tobacco control
Estimates of government expenditures on tobacco control suffer
from several methodological constraints. In 2007 and again in
2008, the WHO Tobacco Free Initiative (WHO/TFI) requested
member states to report expenditures on national tobacco
control programmes.
21 28 In the ﬁrst report, fewer than half of
WHO member states provided information on their tobacco
control expenditures and in the second report the response rate
was still below 60%. The WHO nonetheless estimated that
governments ‘spent a total of $965 million on tobacco
controldwith 99% of this amount spent by 17 high income
countries.’
27 Whether or not this sum included funding by sub-
national governments or funds for international programming is
not made clear.
The challenges faced by WHO/TFI in gathering data on global
funding for national tobacco control programmes is paralleled by
challenges the Framework Convention on Tobacco Control
(FCTC) Secretariat faced in gathering data on funding for global
tobacco control, such as the development assistance for health
(DAH) provided by governmental or private organisations or
individuals. After attempting to quantify this support in 2005,
the WHO FCTC Secretariat concluded it was ‘impossible to
provide a clear indication of the amounts of funding available.’
29
Although parties to the FCTC are required to report whether
they received or provided ﬁnancial or other forms of assistance,
they are not required to quantify this support.
30
One of the most active supporters of global tobacco control,
the Bloomberg Philanthropies, suggested in 2007 that $200
million was spent on international development aid for tobacco
control.
22 The basis for their estimate was not stated, but it may
have included the annual budget for the functioning of the
Framework Convention on Tobacco Control (now $6.5
million),
31 the portion of the WHO budget for tobacco, alcohol,
unhealthy diets, physical activity and unsafe sex (the total of
which is now $80 million) that is spent on tobacco control,
32
and the estimated annual $62 million investment of the
Bloomberg Initiative to Reduce Tobacco Use.
33 Since that esti-
mate was made, a further $25 million annualised donation was
announced in 2008 by the Bill and Melinda Gates Foundation,
34
and WHO/TFI produced an estimate of $9.6 million spent on
national tobacco control programmes in middle-income and
low-income countries. Based on these available estimates, the
total available for development assistance for tobacco control is
likely no greater than $240 million.
Comparison with development assistance for health to control
other diseases
Investments in international assistance for tobacco control from
both governmental and private sources is much smaller than
investments in other identiﬁed global health challenges, on both
an absolute and relative basis. A recent review of DAH estimated
the total ‘ﬁnancial and in-kind contributions from global health
channels that aim to improve health in developing countries’
between 1990 and 2007.
35 This study identiﬁed support for
HIV/AIDS, tuberculosis and malaria, but did not provide esti-
mates for development assistance for tobacco control. Using the
adjusted estimate of DAH for tobacco control provided by the
Bloomberg Foundation, discussed above, and combining
measures of DAH with estimates of the current and future
burden of these diseases
36 37 shows that DAH for each person
living with HIV/AIDS ($111 per year), or tuberculosis ($50) far
exceeds the amount provided for each person who smokes
($ 0.25). (Global estimates for malaria cases are not available.)
When investments in preventable disease control are measured
against predicted deaths in 2030,
38 the funding for malaria
($1189), for tuberculosis ($1127), and HIV/AIDS ($782) again
greatly exceed the funding to prevent tobacco-caused disease
($35). These results are shown in table 4.
Tobacco control has not beneﬁted, as have other diseases with
large global mortality, from the development of new mecha-
nisms to provide ﬁnancial development assistance for health,
such as the Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM) and the Global Alliance for Vaccines and Immunisa-
tion (GAVI). Nor have innovative fund raising programmes to
ﬁnance such instruments been developed for tobacco control as
they have been developed for other global diseases during recent
years. Such programmes include: the Advance Market
Commitment for Vaccines (AMC),
41 which uses price guaran-
tees as incentives to for corporations to develop vaccines for
diseases found in low-income countries; the International
Finance Facility for Immunisation (IFFIm), which issues bonds
in the capital market to raise funds for immunisation
42;
UNITAID, which buys drugs with monies raised through taxes
on air tickets and other revenues
43; Bono and Bobby Shriver’s
private-sector cause-marketing project (RED), which provides
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projects in Africa
44; and the Debt2Health, which allows
borrowing and lending nations to make debt-swaps to free up
domestic resources to address HIV/AIDS, tuberculosis and
malaria.
45
DISCUSSION
The globalisation of the tobacco market has resulted in signiﬁ-
cant transnational transfers of revenues from tobacco sales. The
globalisation of tobacco control, in the form of the FCTC, has
not yet resulted in signiﬁcant transnational transfers of revenues
to support tobacco control efforts.
Global concentration of the tobacco industry could allow for
increased funds to be made available for global efforts to reduce
tobacco use through the use of transaction taxes on the ﬂow of
proﬁts from countries where multinational tobacco companies
sell cigarettes to countries where they distribute the proﬁts or
other ﬁscal instruments. This could reverse the current pattern,
which sees money ﬂow from smokers in developing countries to
corporations in the developed world. It would also be consistent
with the ‘polluter pay’ principle and with proposals like the
Tobin Tax to levy ﬁnes on international ﬁnancial transactions. A
precedent for surtaxes on tobacco companies can be found in
Canada, where the government levied a ‘health promotion
surtax’
46 on tobacco manufacturers’ earnings in 1994, now set at
150% of the tax rate for all other corporations.
47
The imbalance between the money that ﬂows from (often
poor) smokers to (often not poor) shareholders and the money
that ﬂows from wealthy to poor countries to reduce tobacco use
can be illustrated by comparing the earnings received by just one
tobacco company from smokers in one sub-continent with the
amount provide to help all poor nations combat tobacco use. In
2005, BATreported to investors that it sold 40 billion cigarettes
in two of the world’s poorest regions, Equatorial and West
Africa, and that a similar number of cigarettes were sold in the
region by all other companies combined.
48 Assuming the proﬁts
on BAT’s sales in that region were consistent with its average
earnings that region ($0.17 per package of 20 cigarettes, shown
in table 1), then smokers in the poorest countries of sub-Saharan
Africa provided about $340 million to BAT’s bottom line, about
140% the global DAH for tobacco control. Equivalent ﬁgures for
earnings from tobacco sales by other companies in that region
are not disclosed, but would further increase the gap between
the amount provided by Africans and the amount available to
them.
The same governments and international agencies that have
adopted innovative mechanisms and partnerships to raise funds
for other global health challenges have so far failed to do so for
tobacco, although they have developed in domestic tobacco
control several models for how this could be done. Canada’s
health promotion surtax on tobacco manufacturers’ income,
mentioned above, is one available tax instrument. California,
Switzerland and other jurisdictions have imposed special
Table 3 Taxes remitted by largest tobacco companies, 2008 (millions)
Company
Fiscal year
end
Global market
share Tobacco taxes Income taxes Total
US$ US$ US$
China National Tobacco Company (CNTC) 31-Dec-08 38% CNY 449900 71915 y 71915
British American Tobacco and Associates (BAT) 31-Dec-08 16.4% GBP 21799 40012 GBP 1025 1881 41893
Philip Morris International (PMI) 31-Dec-08 15.5% 3935 2787 6722
Japan Tobacco (JTI) 31-Mar-09 10.9% JNY 2016019 19489 JNY 199759 1931 21420
Imperial Tobacco Group (ITG) 30-Sep-08 5.9% GBP 10412 19111 GBP 180 330 19441
Altria/Philip Morris USA 30-Dec-08 3% 3399 1699 5098
Thai Tobacco Monopoly 31-Dec-06 1% BHT 38920 1180 y 1180
Reynolds American 31-Dec-08 * 1890 790 2680
Lorillard 31-Dec-08 <1% 712 547 1259
Total 91% 161,642 9,966 171,608
*Included with BAT total.
yNot available or not found.
Table 4 Development assistance for control selected preventable disease
DAH to developing
countries for
speciﬁc diseases
(2007)
People living with
disease/smoking in
middle and low-
income countries
DAH for every
person living with
speciﬁed disease
or smoking
Estimated deaths
2005 in middle and
low-income
countries
DAH per estimated
death in low and
middle-income
countries 2005
Predicted deaths in
low and middle-
income countries
2030
DAH per estimated
death in low and
middle-income
countries 2030
US$ millions US$ Millions US$ Millions US$
HIV/AIDS 5068 45541113 111.28 2808545 1804.49 6478081 782.33
Source 35 37 38 38
Malaria 761 887835 857.14 639940 1189.17
Source 35 38 38
Tobacco use 240 959000000 0.25 3800000 63.16 6800000 35.29
Source 27 30 39 36 40 40
Tuberculosis 687 13547995 50.71 1397407 491.62 609459 1127.23
Source 35 37 38 38
DAH, development assistance for health.
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tobacco control and other health programming.
49 50
Governments could draw on the same innovative spirit they
used to develop novel instruments to fund efforts against HIV/
AIDS, tuberculosis and malaria in order to ﬁnd a suitable
mechanism to increase funding available to development assis-
tance for tobacco control. The experience with these other
diseases suggests that when there is a political will, a way to
raise money can be found.
The FCTC provides a forum appropriate for intergovern-
mental negotiation of ways to reduce the transboundary ﬂow of
earnings from tobacco use and to increase transboundary
support for tobacco control. Actions the Conference of Parties
and the FCTC Secretariat could take include:
< Monitoring the application of the Article 5.3 guidelines on
tobacco industry inﬂuence which recommend against invest-
ments by governments in tobacco companies, and reporting
on the dividends paid to governments that refuse to abide by
these guidelines.
< Requesting parties to gather and report information on
earnings of the tobacco industry in their country, and also to
report on the destination of those earnings.
< Requesting WHO/TFI to include in its study of ways to
implement FCTC Article 6 (tax and price) methods, currently
under way, the use of proﬁt taxes to raise funds for national
and international tobacco control efforts.
Diverting a portion of the earnings on tobacco sales that cross
international boundaries away from shareholders and towards
the victims and potential victims of this commercial activity
might be one way to resolve the funding crisis that hinders full
implementation of the FCTC.
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What this paper adds
< Revenues generated through tobacco sales by multinational
corporations can be monitored through corporate reports.
< Public investments to reduce tobacco use are extremely small
compared with both corporate proﬁts and government
revenues from cigarette sales. They are also much smaller
than public investments in other high-burden health issues.
< Amechanismtocaptureashareoftheearningsontransnational
tobacco sales could be developed through the Framework
Convention on Tobacco Control and be used to increase
available resources to reduce the burden of tobacco use.
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